So far, so good
TEL AVIV, Israel—BioLineRx Ltd. recently announced that preliminary data from its Phase 2a COMBAT/KEYNOTE-202 study showed that a combination regimen of BL-8040, Keytruda and chemotherapy produced high response and disease control rates in metastatic pancreatic cancer patients. BL-8040 is an inhibitor of the CXCR4 chemokine receptor, which plays a role in tumor growth, metastasis, angiogenesis and therapeutic resistance. Of 15 evaluable patients, four showed a partial response by the data cutoff date of Sept. 30, with eight patients presenting with stable disease. Median progression-free survival and overall survival were not yet reached by the cutoff date, and the combination regimen was generally well tolerated; 15 serious adverse events were reported, and two patients discontinued the study. The data were presented at ESMO IO 2019.